Levothyroxine Recall Statistics in US 2026 | FDA Nationwide Recall, Impact & Facts

Levothyroxine Recall in US 2026

Levothyroxine, the synthetic thyroid hormone taken daily by tens of millions of Americans, is at the center of a nationwide FDA Class II recall that began in July 2026. Major Pharmaceuticals, based in Indianapolis, Indiana with corporate offices in Dublin, Ohio, voluntarily recalled multiple lots of its levothyroxine sodium tablets after internal testing found the pills were subpotent — meaning they contained less active hormone than stated on the label. The U.S. Food and Drug Administration classified the action as a Class II recall on July 17, 2026, a designation reserved for products where use “may cause temporary or medically reversible adverse health consequences” but where the probability of serious harm is considered remote.

This report compiles the newest verified statistics on the 2026 levothyroxine recall, sourced directly from the FDA’s enforcement report, the company’s own recall notice, and cross-checked news coverage citing the FDA record. It covers the exact lots, strengths, and expiration dates affected, the clinical reasoning behind the Class II designation, how this recall fits into levothyroxine’s broader and recurring history of potency-related FDA actions, and what the 22 to 23 million Americans who take this medication daily need to know. Every figure below traces back to the FDA’s official recall notice or its enforcement database.

Interesting Facts: Levothyroxine Recall in US 2026

Source: U.S. Food and Drug Administration, enforcement report and recall notice, July 2026; Major Pharmaceuticals company announcement; contemporaneous news coverage citing the FDA notice (NBC, WKYC, Rolling Out, Healthline, July 2026).

The scale of this recall is best understood through what levothyroxine represents in American healthcare: it was the single most-filled prescription medication in the United States in 2023, ahead of vitamin D, amoxicillin, and lisinopril, with somewhere between 22 and 23 million Americans taking it daily to manage hypothyroidism, a condition affecting an estimated 11.7% of the US population. Because levothyroxine is a hormone replacement rather than a symptom-treating drug, its effectiveness depends on delivering a precise, consistent dose — the entire therapeutic model assumes each tablet supplies the specific microgram amount printed on the label. When manufacturing testing found that certain lots fell short of that standard, the FDA’s subpotent classification reflected a real, if generally modest, clinical concern rather than a routine labeling technicality.

What makes this recall notable in scope, if not necessarily in severity, is its breadth: 12 distinct lots spanning seven different strengths — from the lowest 25 microgram dose up to the highest 150 microgram dose — were named in the FDA’s enforcement report, with expiration dates stretching from this month through January 2027, meaning affected product could plausibly still be sitting in patients’ medicine cabinets or pharmacy shelves for months to come. Crucially, because this is a retail-level recall, pharmacies and health systems are not required to directly contact patients who may have already been dispensed the affected tablets — placing the burden on consumers themselves to check their own lot numbers against the FDA’s published list.

Timeline of the July 2026 Major Pharmaceuticals Recall

LEVOTHYROXINE RECALL TIMELINE — JULY 2026
════════════════════════════════════════════════════════════
  Jul 13, 2026       Major Pharmaceuticals initiates voluntary recall
  Jul 17, 2026       FDA classifies recall as Class II (4 days later)
  Jul 24-31, 2026    National media coverage of recall expands
  Ongoing            Affected lots remain on pharmacy shelves nationwide
════════════════════════════════════════════════════════════

Source: FDA enforcement report; Major Pharmaceuticals company announcement, July 2026.

The four-day gap between Major Pharmaceuticals initiating its voluntary recall on July 13 and the FDA formally classifying it as Class II on July 17 reflects the standard regulatory review process: companies identify a quality issue and act first, while the FDA subsequently evaluates the health risk and assigns the appropriate classification level based on its own review of potency test data and clinical risk. This sequence — company-initiated action followed by federal classification — is the typical pathway for voluntary recalls, which make up the overwhelming majority of all pharmaceutical recalls in the United States, as opposed to the rarer FDA-mandated recalls.

The recall’s retail-level designation is a detail with real practical consequences for patients. Under FDA rules, retail-level recalls direct pharmacies and distributors to pull affected product from shelves and inventory, but they do not require pharmacies to individually contact patients who have already received the medication in a filled prescription. This means the responsibility largely falls on patients and caregivers to proactively check the lot number on their own prescription bottle or blister pack against the FDA’s published list — a detail that dermatologist and toxicology expert Dr. Cutler, quoted in coverage of the recall, noted reflects confidence that the risk to already-dispensed medication is low enough not to warrant the more resource-intensive patient-level notification process used in higher-risk recalls.

Affected Lots, Strengths, and Packaging in the 2026 Levothyroxine Recall

RECALLED LEVOTHYROXINE STRENGTHS AND EXPIRATION WINDOW
════════════════════════════════════════════════════════════
  25 mcg    ████  Lot N02212           Exp. Jul 2026
  50 mcg    ████  Lot N02200           Exp. Oct 2026
  75 mcg    ████  Lots N02172,         Exp. Jul/Dec 2026
                  N02296, N02288
  88 mcg    ████  Lot N02203           Exp. Sep 2026
  125 mcg   ████  Lot N02266           Exp. Nov 2026
  150 mcg   ████  Lots N02167,         Exp. Jul 2026
                  N02167A
════════════════════════════════════════════════════════════

Source: FDA enforcement report, July 2026; company recall notice, Major Pharmaceuticals, cited by WKYC, WFTV, and Boston 25 News, July 2026.

The recalled tablets span the full range of standard levothyroxine dosing, from the smallest commonly prescribed strength at 25 micrograms up through 150 micrograms, reflecting that the manufacturing quality issue was not isolated to a single dose strength but affected multiple production lots across the company’s product line. Both 100-count cartons (10-by-10 unit-dose blister packs) and smaller 10-count cartons (distributed in part by Cardinal Health) were named in the recall, meaning the affected product reached patients through multiple packaging formats and at least two points in the distribution chain.

For patients wanting to check whether their own medication is affected, the FDA’s enforcement report specifies exact lot numbers, National Drug Code (NDC) numbers, and expiration dates, all of which appear on the medication bottle, blister card, or carton itself. Patients are advised to compare these details directly against the FDA’s published recall notice rather than relying on the strength or general appearance of the tablet alone, since Major Pharmaceuticals manufactures multiple lots of each strength continuously, and only the specific lots listed above are affected by this particular recall.

Why Subpotent Levothyroxine Matters: The Clinical Health Impact

CLINICAL IMPACT OF SUBPOTENT LEVOTHYROXINE
════════════════════════════════════════════════════════════
  Risk classification         Class II — temporary/reversible
  Primary clinical concern    Return of hypothyroid symptoms
  Monitoring safeguard        Routine TSH blood testing
  Company's own risk stance   "Unlikely to cause adverse effects"
  Long-term damage risk       Low — caught via bloodwork before harm
════════════════════════════════════════════════════════════

Source: FDA Class II recall classification criteria; Healthline reporting citing endocrinology expert commentary, July 2026; clinical guidance on levothyroxine monitoring.

Levothyroxine works by replacing a hormone the thyroid gland can no longer adequately produce on its own, so a tablet containing less active ingredient than its label states can allow the symptoms of hypothyroidism — fatigue, unexplained weight gain, sensitivity to cold, and difficulty concentrating — to gradually reemerge in a patient who believes their condition is being fully managed. This is precisely the clinical logic behind the FDA’s Class II designation: the risk is real and worth correcting, but it is generally temporary and medically reversible, rather than posing an immediate or high probability of serious, lasting harm.

The built-in safeguard that limits the real-world impact of this kind of recall is routine thyroid monitoring. Patients on levothyroxine are typically directed to undergo periodic blood tests measuring thyroid-stimulating hormone (TSH) levels, and clinicians interviewed about the recall have noted that this existing monitoring infrastructure would likely catch a meaningful drop in thyroid hormone levels before it caused significant health consequences, since abnormal TSH results prompt dose adjustments as a matter of routine clinical practice. The population considered at somewhat elevated risk from any prolonged period of underdosing includes adults over 80, for whom thyroid hormone imbalances of any kind — too much or too little — carry a higher documented risk of cardiovascular complications.

FDA Recall Classification System: How Class II Compares

FDA DRUG RECALL CLASSIFICATION LEVELS
════════════════════════════════════════════════════════════
  Class I    ████████████████████████████  Reasonable probability of
                                             serious harm or death
  Class II   ████████████████              Temporary/reversible
             (2026 levothyroxine recall)    consequences; serious harm remote
  Class III  ████                          Unlikely to cause any
                                             adverse health consequences
════════════════════════════════════════════════════════════

Source: FDA recall classification definitions, 21 CFR Part 7; FDA enforcement report for the 2026 levothyroxine recall.

Understanding where “Class II” sits within the FDA’s three-tier recall classification system helps put this recall in proper context. Class I recalls — the most serious tier — are reserved for situations where the FDA determines there is a reasonable probability that using the product will cause serious adverse health consequences or death; these are relatively rare and often involve contamination, mislabeling with life-threatening dosage errors, or similarly severe defects. At the opposite end, Class III recalls apply to violations that are unlikely to cause any adverse health consequences at all, often involving minor labeling or packaging issues unrelated to the drug’s actual safety or efficacy.

The Class II designation assigned to this levothyroxine recall sits deliberately in the middle: the FDA has determined that using the subpotent tablets could plausibly cause temporary, reversible harm — the return of hypothyroid symptoms being the primary concern — but that the probability of serious, lasting harm is remote. This is also, notably, a common classification for potency-related pharmaceutical recalls generally, since manufacturing variance that falls modestly outside specification thresholds rarely poses the kind of acute danger associated with Class I actions like contamination or severe overdose risk. Readers wanting broader context on how the US pharmaceutical pricing and regulatory system operates around medications like this one can find additional detail in the prescription drug price statistics for the US, which covers the wider landscape of drug affordability, generic competition, and regulatory reform shaping the market this same medication is sold within.

Levothyroxine’s Place in the American Medication Landscape in 2026

LEVOTHYROXINE USAGE AND MARKET POSITION — US
════════════════════════════════════════════════════════════
  Rank among all US prescriptions (2023)         #1 (most filled)
  Americans currently taking levothyroxine       22-23 million
  US prescriptions filled annually (2021 data)   89 million
  Hypothyroidism prevalence (2019)               11.7% of population
  Female-to-male usage ratio                     5-9x more common in women
  Share now taking generic formulations          ~80%
════════════════════════════════════════════════════════════

Source: RestartMed compilation of NIH/CDC hypothyroidism data; Yale School of Medicine, “21 Million Americans May Take a Hypothyroidism Drug They Don’t Need,” citing 2021 study; Statista prescription volume data, 2023.

Levothyroxine’s status as the single most-prescribed medication in the United States — ahead of vitamin D supplements, amoxicillin, and the blood pressure medication lisinopril in 2023 filled-prescription rankings — means that even a recall affecting a relatively small fraction of total manufactured lots touches an enormous population by sheer scale. With somewhere between 22 and 23 million Americans currently taking the drug and 89 million total prescriptions filled in 2021 alone (reflecting refills across the year, not unique patients), levothyroxine sits in a category of medications where quality control issues inherently carry wide reach, even when clinical severity per affected patient remains modest.

The medication’s usage patterns also help explain who is most likely to be affected by any given recall. Hypothyroidism affects women at five to nine times the rate of men, and prevalence has been documented to be rising, from 9.6% of the US population in 2012 to 11.7% by 2019. A notable and separate area of ongoing research — highlighted by a Yale School of Medicine-affiliated 2021 study — has found that as many as 90% of a studied population of levothyroxine users may not have needed the prescription in the first place, due to natural seasonal variation in thyroid hormone levels that current testing protocols do not always account for. This overprescription research is a distinct issue from the current potency recall, but it underscores that levothyroxine’s enormous patient population reflects both genuine clinical need and, according to some researchers, a meaningful degree of prescribing that may not always be strictly necessary.

Levothyroxine’s Recurring History of Potency Recalls in the US

RECENT LEVOTHYROXINE POTENCY-RELATED RECALLS — US TIMELINE
════════════════════════════════════════════════════════════
  Nov 2024   Mylan/Viatris recall — atypical assay results, retail level
  Jun 2025   Accord Healthcare — 82,159 bottles, 25 mcg, Class II
  Jul 2026   Major Pharmaceuticals — 12 lots, 7 strengths, Class II
════════════════════════════════════════════════════════════

Source: FDA enforcement reports, 2024–2026; California Board of Pharmacy recall alert archive; Healthline reporting citing separate FDA enforcement records, July 2026.

The July 2026 Major Pharmaceuticals recall is not an isolated event but the latest in a recurring pattern of levothyroxine potency issues that has played out across multiple manufacturers over the past several years. In November 2024, Mylan Pharmaceuticals (a Viatris company) conducted a retail-level recall of levothyroxine lots distributed between August 2023 and November 2024, citing atypical or out-of-specification assay results, though the company characterized the patient risk as negligible. Just months later, in June 2025, Accord Healthcare recalled 82,159 bottles of its 25 microgram levothyroxine tablets, again for subpotency, and again receiving a Class II classification from the FDA.

Public health researchers interviewed about the pattern have offered a notably reassuring interpretation: rather than signaling a worsening safety problem, the recurring recalls demonstrate that the FDA’s ongoing potency monitoring system is functioning as intended. As one expert quoted in coverage of the current recall explained, every stage of the manufacturing and distribution pathway — from the drug manufacturer through distribution to the pharmacy counter — is continuously monitored for potency, and routine inspections are what catch these issues before they reach a level of concern requiring more severe Class I action. Because levothyroxine has a famously narrow therapeutic index — meaning the difference between an effective dose and an ineffective or excessive one is comparatively small — and because it has historically been manufactured by numerous competing companies since going generic, it may simply be more prone to periodic potency findings than medications with wider dosing tolerance or fewer manufacturers. Readers curious about how this compares to potency and safety issues across an entirely different consumer product category can see a similarly patterned, though far larger-scale, example in the vehicle recall statistics for the US, where a recurring cycle of manufacturer recalls and federal classification plays out at a much larger volume.

What Levothyroxine Patients Should Do in Response to the 2026 Recall

PATIENT ACTION STEPS — 2026 LEVOTHYROXINE RECALL
════════════════════════════════════════════════════════════
  Step 1   Check bottle/blister for "Major Pharmaceuticals" or
           "Cardinal Health" as the packager/distributor
  Step 2   Compare lot number and NDC to the FDA's published list
  Step 3   If NOT affected: continue taking medication as prescribed
  Step 4   If affected: consult pharmacist or doctor before stopping
  Step 5   Continue routine TSH blood testing as scheduled
════════════════════════════════════════════════════════════

Source: FDA recall guidance for consumers; Healthline and AARP consumer reporting on the July 2026 recall.

The consistent guidance across pharmacists, endocrinologists, and the FDA itself is that patients should not simply stop taking levothyroxine out of caution if they discover their medication may be part of the recalled lots — abruptly discontinuing thyroid hormone replacement carries its own, separate risks and should never be done without first consulting a pharmacist or physician. The practical first step is simply checking the medication bottle or blister pack for the manufacturer name (Major Pharmaceuticals or Cardinal Health as distributor), then comparing the specific lot number and expiration date against the FDA’s published recall notice.

Because thyroid hormone management already relies on periodic blood testing as a standard part of ongoing care, patients on any batch of levothyroxine — recalled or not — benefit from maintaining their regularly scheduled TSH monitoring appointments, which serve as the most reliable real-world check on whether their current medication supply is delivering an effective dose. For readers interested in how this particular thyroid medication recall fits within the much broader landscape of thyroid-related health conditions Americans face — including the roughly 45,000 new thyroid cancer diagnoses projected for 2026 — the thyroid cancer statistics for the US provide a comprehensive look at the wider clinical picture surrounding this same gland and the medications, including levothyroxine, used to manage both cancerous and non-cancerous thyroid conditions.

Disclaimer: This research report is compiled from publicly available sources. While reasonable efforts have been made to ensure accuracy, no representation or warranty, express or implied, is given as to the completeness or reliability of the information. We accept no liability for any errors, omissions, losses, or damages of any kind arising from the use of this report.

Email ID:

Please enable JavaScript in your browser to complete this form.

Email

Email *

SUBSCRIBE